CAMBRIDGE, Mass. - Leap Therapeutics, Inc. (NASDAQ:LPTX), a clinical-stage biotech company with a market capitalization of $86 million and an overall "Fair" financial health rating according to ...
A data analysis from a randomized clinical trial for stage 3 colon cancer patients found that patients with evidence of residual cancer in their blood after surgery to remove the cancer, may benefit ...